Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2303-2311

  Henry, N Lynn ^a   Somerfield, Mark R ^b   Abramson, Vandana G ^c   Allison, Kimberly H ^d   Anders, Carey K ^g   Chingos, Diana T ^e   Hurria, Arti ^f   Openshaw, Thomas H ^h   Krop, Ian E ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h EASTERN MAINE MEDICAL CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER SIZE; CLINICAL FEATURE; COMORBIDITY; CONFLICT OF INTEREST; EMBASE; HUMAN; LYMPH VESSEL METASTASIS; MEDICAL SOCIETY; MEDLINE; MENOPAUSE; MICROMETASTASIS; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; DECISION MAKING; FEMALE; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84976389243     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8609     Document Type: Article

References (20)

1. Eisen A, Fletcher GG, Gandhi S, et al; members of the Early Breast Cancer Systemic Therapy Consensus Panel: Optimal systemic therapy for early breast cancer in women: A clinical practice guideline. Curr Oncol 22:S67-S81, 2015 (Suppl 1)
2. Coates AS, Winer EP, Goldhirsch A, et al: Tailoring therapies-Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
3. Brouwers MC, Kho ME, Browman GP, et al: AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ 182: E839-E842, 2010
4. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016
5. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005-2014, 2015
6. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
7. Wildiers H, Heeren P, Puts M, et al: International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32:2595-2603, 2014
8. Early Breast Cancer Trialists' Collaboration Group, Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level metaanalysis of randomised trials. Lancet 378:771-784, 2011
9. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907-922, 2010
10. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
11. Trudeau ME, Pritchard KI, Chapman JA, et al: Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 89:35-45, 2005
12. Song YJ, Shin SH, Cho JS, et al: The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. J Breast Cancer 14:198-203, 2011
13. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes: Dealing with the diversity of breast cancer-Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011
14. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
15. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
16. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
17. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725, 2005
18. Campbell HE, Taylor MA, Harris AL, et al: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101:1074-1084, 2009
19. Galimberti V, Cole BF, Zurrida S, et al: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol 14:297-305, 2013
20. Jafferbhoy S, McWilliams B: Clinical significance and management of sentinel node micrometastasis in invasive breast cancer. Clin Breast Cancer 12:308-312, 2012